Core Viewpoint - Zhejiang Apac Pharmaceutical Co., Ltd. has made significant progress in the transfer of control, with the Shenzhen Stock Exchange confirming the share transfer agreement, indicating a successful transition of control to Xinghao Holdings and its actual controller, Mr. Qiu Zhongxun [1][2] Group 1: Control Transfer Details - The share transfer involves a 14.61% stake at a price of 8.26 yuan per share, totaling 900 million yuan, marking a significant change in the company's control [1] - The new actual controller, Mr. Qiu Zhongxun, has over 20 years of experience in the pharmaceutical industry and is the chairman of Yaodou Technology, a leading digital pharmaceutical platform [2] Group 2: Financial and Strategic Implications - The control transfer includes a plan for a private placement of up to 700 million yuan, aimed at funding new drug research and development projects [2] - The confidence shown by the new controller through the private placement is expected to ensure the long-term stability and sustainable development of the company [2] Group 3: Future Development and Innovation - Apac Pharmaceutical is committed to transforming into an innovative drug company, focusing on a combination of generic and innovative drug development [4] - The company has 114 approved drug formulations, with 19 products having passed consistency evaluations, and is expected to benefit from the national drug centralized procurement [4][5] - The collaboration with Yaodou Technology is anticipated to enhance the commercialization of innovative products, improving the efficiency of research outcomes and providing a competitive edge in the market [5]

Core Insights - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, with 50 classified as innovative drugs, achieving an overall success rate of 88%, a significant increase from 76% in 2024 [4][8] - The new drug list will be implemented starting January 1, 2026, as announced during the 2025 Innovative Drug High-Quality Development Conference held in Guangzhou [4][5] Summary by Category National Medical Insurance Drug List - The 2025 National Medical Insurance Drug List includes drugs that address gaps in basic medical insurance coverage, such as treatments for triple-negative breast cancer, pancreatic cancer, and lung cancer [4][8] - The total number of drugs in the National Medical Insurance Drug List has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, enhancing coverage for key areas like cancer, chronic diseases, mental health, rare diseases, and pediatric medications [4][8] Commercial Health Insurance Innovative Drug List - The first edition of the commercial health insurance innovative drug list includes 19 new drugs, featuring CAR-T therapies for cancer treatment, as well as treatments for neuroblastoma, Gaucher disease, and Alzheimer's disease [4][8]

Core Insights - The new National Medical Insurance Directory has added 114 new drugs, surpassing last year's addition of 91, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, an improvement from 76% in 2024 [1][2] Group 1: New Drug Additions - The total number of drugs in the directory has increased to 3,253, significantly enhancing coverage for key areas such as oncology and chronic diseases [2] - The directory includes 38 global innovative drugs and 50 first-class innovative drugs, marking a historical high for new additions [2] - Notable inclusions are the first globally approved red blood cell maturation agent, Rotecip, for treating lower-risk myelodysplastic syndromes, and the first domestically developed IL-4Rα antibody drug, Kangyueda, for multiple indications [3][4] Group 2: Oncology Innovations - Several innovative oncology drugs have been added, including Tagolizumab, the first PD-L1 monoclonal antibody approved for nasopharyngeal carcinoma, and non-covalent BTK inhibitor, Jebatib, for relapsed mantle cell lymphoma [4][5][6] - ADCs (antibody-drug conjugates) have gained attention, with new entries like Lukanasatuzumab and Ruikangquzuzumab, targeting advanced breast cancer and non-small cell lung cancer [7][8] Group 3: Chronic Disease Treatments - The directory has included innovative drugs for chronic diseases, such as Novartis' PCSK9 mRNA interference drug for cholesterol management, addressing patients who cannot reach LDL-C targets [14] - AstraZeneca's biologic drug Benralizumab for severe eosinophilic asthma has also been added, providing targeted treatment options for patients [15][16] Group 4: Influenza Treatments - The new directory has incorporated two domestic antiviral drugs for influenza, Masurashave and Angladiv, which have shown promising clinical results in reducing symptoms and viral load [17]

2025 年 12 月 08 日 再提"实现量的合理增长" ——2025 年 12 月政治局会议点评 联系人 程翔 A0230518080007 chengxiang@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 策 略 研 究 证 券 研 究 报 告 请务必仔细阅读正文之后的各项信息披露与声明 相关研究 程翔 A0230518080007 chengxiang@swsresearch.com 傅静涛 A0230516110001 fujt@swsresearch.com 王胜 A0230511060001 wangsheng@swsresearch.com A 股 策 略 - 证券分析师 ⚫ 本次政治局会议工作基调与年中保持一致，重点强调"坚持稳中求进工作总基调，统筹发 展和安全"的同时提出了"增强政策前瞻性针对性协同性，持续扩大内需、优化供给，做 优增量、盘活存量" 。结构方面再次强调"因地制宜发展新质生产力，纵深推进全国统 一大市场建设，持续防范化解重点领域风险"。细节方面可以看到，2025 年连续两次政 治局会议提及"实现量的合理增长"，时隔半年政治局会议再提"更好统 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 自願公告 安 奈 拉 唑 鈉 腸 溶 片（商 品 名：安 久 衛®）於 二 零 二 三 年 六 月 獲 得 中 國 國 家 藥 品 監 督 管 理 局 批 准 上 市，用 於 患 者 治 療 十 二 指 腸 潰 瘍。安 奈 拉 唑 鈉 擁 有 創 新 的 結 構 設 計，具 有 非 酶 加 多 酶 代 謝、均 衡 腸 腎 雙 通 道 排 泄 等 特 點，僅3.5%經CYP2C19代 謝，這 使 其 不 受CYP2C19基 因 多 態 性 影 響。與 前 幾 代 質 子 泵 抑 制 劑 相 比，安 奈 拉 唑 鈉 合 併 用 藥 的 風 險 小，對 多 重 用 藥 患 者、腎 功 能 不 ...

商业航天板块多股连板，航天科技、西部材料等2连板。一图速览今日连板股>> 12月8日，Wind数据显示，A股市场共计78只个股涨停。其中创新药板块瑞康医药收获4连板，人形机器 人概念股骏亚科技4连板；商业航天板块多股连板，航天科技、西部材料等2连板。一图速览今日连板股 >> | | 连板服投 12.8 一板 | | | --- | --- | --- | | 股票名称 | 连板天数 | 所属概念 | | 安记食品 | 5 | 调味品 | | 瑞康医药 | 4 | 创新药 | | 龙洲股份 | 4 | 机器人 | | 骏亚科技 | 4 | 人形机器人 | | 双星新材 | 3 | 基础化工 | | 舒华体育 | 3 | 体育产业 | | 冰轮环境 | 2 | 液冷+核聚变 | | 航天科技 | 2 | 商业航天+卫星导航 | | 厦门港务 | 2 | 港口物流 | | *ST钢昌 | 2 | 商业航天 | | 南矿集团 | 2 | 黄金 | | 西部材料 | 2 | 商业航天+可控核聚变 | | 精艺股份 | 2 | 铜 | | 顺灏股份 | 2 | 商业航天 | | 闽发铝业 | 2 | 铝 | | 福建金森 ...

Core Insights - The global biopharmaceutical innovation landscape is undergoing a significant structural change, with China's innovative drug industry emerging as a key player on the global stage, transitioning from a "fast follower" to a "first mover" [2] - China's share in global clinical trials and licensing transactions has notably increased, with Chinese biotech companies' stock prices outperforming their U.S. counterparts over the past year, indicating a historic investment opportunity [2][3] - The trend of multinational corporations (MNCs) increasingly sourcing early-stage innovation pipelines from China is becoming more pronounced, driven by cost-effectiveness and superior outcomes [3] Group 1 - China's innovative drug companies can advance drug discovery from target identification to IND application 2-3 times faster than international peers, and patient recruitment in clinical development is 2-5 times quicker, with costs per patient being half of those in Europe and the U.S. [5] - The total amount of external licensing transactions for Chinese innovative drugs surpassed $100 billion in the first three quarters of 2025, highlighting the immense potential for value realization in the domestic market [5] - Significant collaborations, such as the $12.5 billion agreement between 3SBio and Pfizer, have sparked renewed interest in the capital market, leading to a 60.27% increase in the Hang Seng Innovation Drug Index in June [3][5] Group 2 - The current surge in business development (BD) activities is driven by MNCs recognizing the continuous improvement in China's innovation, research, and clinical capabilities, prompting large-scale acquisitions [6] - Investment institutions are focusing on the biopharmaceutical sector, where approximately 80% of market value is concentrated, leading to a clear investment path for capital [6][7] - The market is witnessing a shift towards more innovative collaboration models, such as the "Co-Co model" between Innovent Biologics and Takeda, with potential transaction values reaching $11.4 billion [5] Group 3 - The Chinese innovative drug sector is expected to thrive, with projections indicating a prosperous pharmaceutical industry by 2025, supported by favorable policies and recovering valuations [9] - The overall revenue of listed Chinese innovative drug companies reached 48.83 billion yuan in the first three quarters of 2025, marking a 22% year-on-year increase, with the sector achieving its first quarterly profit since its inception [9] - The Hong Kong market is experiencing a threefold increase in trading volume compared to last year, with both domestic and foreign funds actively investing in the Chinese market [9][10] Group 4 - The capital market is transitioning from a focus on narrative-driven investments to a preference for companies with solid fundamentals, emphasizing the importance of clinical data and asset quality [11][12] - The interaction between A-share and Hong Kong markets is tightening, with a trend of high-quality blue-chip assets seeking listings in Hong Kong, reflecting a more rigorous examination of companies' fundamentals [14][15] - Companies with strong fundamentals are more likely to succeed in the capital market, while those lacking solid foundations may struggle to capitalize on market opportunities [16][17]

此外针对目录动态调整中的衔接问题，政策明确过渡期安排，未成功续约被调出目录的协议期内谈判药 品，给予其6个月的过渡期，2026年6月底前医保基金可按原支付标准继续支付。 据了解，奥壹新是具有自主知识产权、全新分子实体、活性显著的口服的第三代EGFR-TKI。目前已获 批两项肺癌适应症，实现对不同治疗阶段患者的精准覆盖，作为结构差异化的新型第三代EGFR-TKI， 奥壹新不仅具备强效的肿瘤抑制活性，更在临床中展现出突出的脑转移治疗优势——这对肺癌患者至关 重要，因为脑转移是EGFR突变NSCLC患者常见的转移部位，也是影响患者生存期与生活质量的重要因 素。临床研究证实，奥壹新在延长患者无进展生存期的同时，能有效提升生活质量，为肺癌慢病化管理 提供有力支撑。 12月7日，国家医保局发布《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险 创新药品目录》(2025年)。据统计，本次医保目录调整共有114种药品新增进入、29种药调出，另有18 家企业的19种药品进入商保创新药目录，并决定于2026年1月1日起正式执行，这也是医保目录调整中首 次同步推出商保创新药目录，形成基本医保与商业健康保险协同保障创 ...

Core Insights - The 2025 Innovation Drug High-Quality Development Conference will be held on December 7 in Guangzhou, where the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory will be released, including the long-acting growth hormone Yipeisheng developed by TEBIO [1] Group 1: Product Development and Market Impact - Yipeisheng is the first globally approved Y-type 40kD polyethylene glycol long-acting growth hormone, reducing the injection frequency from daily to weekly, significantly alleviating the psychological burden on children [2] - The product is preservative-free and features a "single-use" design, greatly reducing the risk of microbial contamination and cross-infection [2] - The accompanying smart electronic injection pen "Yushida" addresses children's fear of injections with an innovative needle-hidden design, allowing for self-administration by older children and enhancing treatment adherence [2] Group 2: Social Responsibility and Public Health - TEBIO is actively engaged in social responsibility through donations to the "Little Bamboo Shoot" children's health care project, focusing on early screening, diagnosis, and standardized treatment of growth disorders [3] - The inclusion of Yipeisheng in the national medical insurance directory is expected to significantly improve accessibility to this innovative drug, reducing the economic burden on families and promoting sustainable treatment options for children's growth disorders [3]

Investment Rating - The report rates multiple companies in the healthcare sector as "Outperform," including BeiGene, China Resources Pharmaceutical, JD Health, Innovent Biologics, WuXi Biologics, and many others [1]. Core Insights - The Hong Kong healthcare sector has shown resilience, with the Hang Seng Healthcare Index gaining 72.2% year-to-date, outperforming the Hang Seng Index by 41.1 percentage points [4][28]. - The implementation of the "dual catalogs" for basic medical insurance and commercial insurance is expected to support innovation in the pharmaceutical sector, with 114 new drugs added to the basic medical insurance catalog and a success rate of 88% [5][30]. - The report highlights the strong performance of the pharmaceutical distribution and CXO sectors, with respective gains of 2.0% and 1.7% in the past week [15][29]. Summary by Sections Market Performance - The Hang Seng Healthcare Index fell by 0.7% in the week of December 1-5, 2025, underperforming the Hang Seng Index by 1.6 percentage points [4][28]. - The pharmaceutical distribution sector and CXO services performed well, with increases of 2.0% and 1.7%, respectively [15][29]. Drug Catalog Implementation - The "National Basic Medical Insurance Catalog" and the first edition of the "Commercial Insurance Innovative Drug Catalog" were released, with 114 new drugs added to the basic insurance catalog [5][30]. - The commercial insurance catalog includes 19 innovative drugs, emphasizing support for innovation and addressing the needs of the elderly and children [13][30]. Company Highlights - Notable companies that performed well include Jinxin Fertility (+7.5%), Harbour BioMed-B (+5.3%), and WuXi Biologics (+4.7%) [15][29]. - The report suggests increasing focus on companies with strong performance certainty in the CXO sector and those with stable long-term demand in medical services [15][29].